Navigation Links
Mersana's Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting
Date:4/19/2009

- Data Show Fleximer(R) Extends Exposure to Conjugated Drug -

CAMBRIDGE, Mass., April 19 /PRNewswire/ -- Mersana, a platform-based cancer therapeutics company, today announced positive results of preclinical studies for its second development candidate, XMT-1107, in two posters at the 2009 Annual Meeting of the American Association of Cancer Research (AACR) in Denver.

The studies showed that XMT-1107, a novel anti-angiogenic fumagillin analog conjugated to Mersana's proprietary Fleximer(R), demonstrated superior anti-tumor activity in tumor xenograft models in comparison to other anti-angiogenic agents and extended exposure to the conjugated drug, supporting the potential clinical utility of XMT-1107 as an anti-cancer agent. Full text of the abstracts can be viewed online at the AACR website at www.AACR.org.

"We're encouraged by the ongoing progress we're seeing with XMT-1107, which targets a novel mechanism to inhibit endothelial cell proliferation and has the potential to target a wide variety of angiogenic tumors," said Julie Olson, Mersana CEO. "Earlier drugs in this class showed promising activity in the clinic but were discontinued due to reversible neurological toxicity. Conjugation of our novel fumagillin 'warhead' to Fleximer using a specific linker technology reduces CNS exposure in animal models to below detection limits. We look forward to advancing XMT-1107 into clinical studies by early 2010."

"Anti-angiogenic and anti-tumor activity of XMT-1107, a fumagillin-derived polymer conjugate, and its in vivo release product XMT-1191"

By Laura C. Akullian, Cheri A. Stevenson, John Benson, Robert J. Fram, Timothy B. Lowinger

This study showed that XMT-1107 has enhanced anti-angiogenic and anti-tumor activity compared to small molecule analogs delivered without the benefit of Fleximer.
'/>"/>

SOURCE Mersana Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Secondhand Smoke Quickly Affects Blood Vessels
2. Every 30 Seconds an African Child Dies from Malaria; Education Key to Prevention
3. Rochester Medical Announces Second Quarter 2009 Earnings Conference Call April 30, 2009
4. Valensa Completes Second Expansion of Astaxanthin Capacity
5. Success of Colorful School Supply Collection Inspired by Leukemia Patient Kicks off Second Year
6. Metro Parents Second Annual Living With Autism Workshop Features Local Experts Who Are Intimately Involved in Improving the Lives of These Special Children
7. Equinox Fitness Clubs Continues National Expansion with the Opening of its Second Boston Location
8. Second European Radiosurgery Workshop Yields Record Attendance
9. Secondhand Smoke Affecting Millions of New Yorkers
10. Hillenbrand Expects to Report Second-Quarter Net Revenue of $170.8 Million and Revises 2009 Guidance
11. MoleSafe USA Opens Second Location in Albuquerque, New Mexico
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... owner of Supreme Ultimate Fitness in Boca Raton, ... his students in the new year. The difference with this ... own prize or against each other. They will be losing ... Society in Boca Raton, FL. ,, "For every ... February 28, 2010 I will donate $10 to the Tri ...
(Date:12/16/2009)... , , TUESDAY, Dec. 15 (HealthDay News) -- If that ... on your life that you just can,t wait to have ... you might want to wait at least six months before ... be even better. , The study found that when ... chances of the baby dying, being born prematurely, having birth ...
(Date:12/16/2009)... received a further 1.6 million Euro in capital funding to ... in order to meet the rapidly growing demand for this promising ... A/S that continue to own each about 50% of the company. ... ... Unisense FertiliTech A/S has received a further 1.6 million Euro ...
(Date:12/16/2009)... announce being presented with the Weatherhead 100 Upstart Award on December ... in Northeast Ohio and is a testament to hard work, commitment, ... ... (PRWEB) December 16, 2009 -- Request A Test, Ltd. ... Award on December 3, 2009. The Weatherhead 100 showcases the ...
(Date:12/16/2009)... will continue to offer free nationwide confidential legal consultations for ... effects such as: Birth Defects, Attempted Suicide, Suicide and Addiction ... free at 1-800-856-6405 or go to the firm’s website at ... form. , ... (PRWEB) December 16, ...
Breaking Medicine News(10 mins):Health News:Fitness Trainer Motivates Clients with Weight Loss to Help Raise Money for Animal Shelter 2Health News:For Babies' Sake, Pregnancy Spacing Matters 2Health News:For Babies' Sake, Pregnancy Spacing Matters 3Health News:Increased Capital Funding for Unisense FertiliTech A/S Will Help Meet Demand for New Assisted Reproduction Device 2Health News:Request A Test Receives Weatherhead 100 Upstart Award 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free Legal Consultations For Users of Paxil 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free Legal Consultations For Users of Paxil 3
... May 29 Britannia members overwhelmingly endorse plans ... to create new super-mutual:- New business will be ... services, providing ethical alternative to banks- Strong strategic ... expected efficiency and revenue benefits of pounds Sterling ...
... WASHINGTON, May 29 The following advisory is being ... http://www.newscom.com/cgi-bin/prnh/20081105/DC44231LOGO ) WHAT: American ... June 4, 10 a.m. WHERE : National Press Club ... American Life League, Pharmacists for Life International, Pro-Life ...
... Beckman Coulter, Inc. (NYSE: BEC ), ... that simplify, automate, and innovate complex biomedical testing, ... president of strategy, will present at the Goldman ... at 11:00 a.m. (ET).(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO )The ...
... Fla.--The vast majority of advanced colon cancer patients in ... of prescription drugs for managing chemotherapy side effects, such ... to reduce drug cost burdens after joining the clinical ... Dana-Farber Cancer Institute in Boston. Although few patients reported ...
... New mushrooms offer 100 percent of recommended daily Vitamin ... Through a truly collaborative research effort with the United ... been successful in replicating what happens in nature when ... light the same way humans do, by converting the ...
... and Long-Term Care to Youth with Special NeedsWASHINGTON, May 29 ... anniversary with the launch of Home at HSC , ... home environment for long-term patients age 6 months to 21 ... provide in a home, group home or typical long-term care ...
Other Medicine News:Health News:Britannia Members Back Super-Mutual Merger With the Co-Operative Financial Services 2Health News:Britannia Members Back Super-Mutual Merger With the Co-Operative Financial Services 3Health News:Britannia Members Back Super-Mutual Merger With the Co-Operative Financial Services 4Health News:The Pill Kills Women: Largest Protest Against Birth Control Pill 2Health News:1 in 10 advanced colon cancer patients worry about prescription drug costs 2Health News:Monterey Mushrooms Launches Vitamin D Enriched Sun Grill-A-Bella and White Mushrooms 2Health News:Home At HSC 2
(Date:12/15/2009)... ZURICH, Ill., Dec. 15 Fenwal Inc., a ... availability for patient care, reiterated its commitment to provide ... lifesaving blood products, despite a new lawsuit filed yesterday ... Fenwal® Alyx® system, introduced in 2003, is an advanced ... red cells from a single donor in about 30 ...
(Date:12/15/2009)... -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) ... 2009 special dividend payment of $1.67 per share to ... 1, 2009. With this payment, distributions to stockholders ... per share. In January 2010, the Company will ... the Company,s 2009 cash distributions and the allocation between ...
(Date:12/15/2009)... Champions Biotechnology, Inc . (OTC ... development of advanced preclinical platforms and tumor specific ... today announced its financial results for the second ... details of Company,s financial results are available in ... ,, Total revenues for the second quarter of ...
Breaking Medicine Technology:Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers 2Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers 3PDL BioPharma Completes December 15 Special Dividend Payment 2Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 5Cepheid Receives FDA Clearance for First On Demand Molecular Diagnostic Test for Clostridium difficile Infection 51429 1Cepheid Receives FDA Clearance for First On Demand Molecular Diagnostic Test for Clostridium difficile Infection 51429 2Cepheid Receives FDA Clearance for First On Demand Molecular Diagnostic Test for Clostridium difficile Infection 51429 3Cepheid Receives FDA Clearance for First On Demand Molecular Diagnostic Test for Clostridium difficile Infection 51429 4Cepheid Receives FDA Clearance for First On Demand Molecular Diagnostic Test for Clostridium difficile Infection 51429 5Spots Still Available to Run 2009 ING New York City Marathon With Team Reeve 51427 1Spots Still Available to Run 2009 ING New York City Marathon With Team Reeve 51427 2Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class 4717 1Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class 4717 2Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class 4717 3
... -, PHOENIX, Sept. 4 Zila, Inc.,s (Nasdaq: ... early detection of,abnormalities which can lead to oral cancer, ... II study of Cetuximab (ERBITUX(R)), a,leading cancer therapeutic for ... IMCL ) and distributed by Bristol-Meyers Squibb (NYSE:,BMY). ...
... Monte Carlo brings predictability to whole range ... of Phase II, III and ... Tourtellotte Solutions, a,global leader in off-the-shelf and custom supply ... today announced,the release of its tcVisualize(TM) 3.0 clinical trial ...
Other Medicine Technology:Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 2Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 3Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator 2
... FLEXILOG antimony pH catheters are designed for patient ... ,All catheters are number marked at 5cm intervals ... than sixteen individual models are available spanning most ... or multi-use models with one or two sensors., ...
... catheter has two sensors and a black ... allowing optimal placement in relation to the ... esophageal pH monitoring. , ,Alpine's VersaFlex ... on the market (4.7 French), and are ...
... Slimline single-use pH catheters are efficient, ... and allow greater patient comfort during ... pH measurement systems have been designed ... allow an accurate room-temperature calibration. The ...
FLEXILOG accessory....
Medicine Products: